Abstract:Histone methyltransferase G9a is a key enzyme for histone H3 dimethylation at lysine-9 (H3K9me2), an epigenetic mark of gene suppression. Knockdown of G9a markedly inhibits the growth of prostate cancer cells. G9a is highly expressed in human liver cancer cells; however, little is known about its role in the pathology of liver cancer. The purpose of the present study was to elucidate the mechanistic role of G9a in liver carcinogenesis, using the specific G9a inhibitor BIX-01294 (IC 50 2 µM). We found that G9a protein was expressed much higher in mouse hepatoma Hepa-1 cells than in mouse liver. Treatment of Hepa-1 cells with BIX-01294 (4 µM) for 24 h and 72 h decreased the number of live cells (MTT assay) by 50 and >90%, respectively. After 24 h exposure of Hepa-1 cells to BIX-01294, there was an 8-fold increase of caspase-3/7 activity, indicating that the anticancer effect of G9a inhibition is due to induction of apoptosis. Also at 24 h, BIX-01294 abolished mRNA expression of Cyclin D1, but induced mRNA expression of C/EBP homolog protein (CHOP), a transcription factor that promotes apoptosis and inhibits the proliferation of hepatoma cells. Silencing of the tumor-suppressor genes PTEN and p21 in cancer cells has been associated with H3K9me2 of their gene promoters. We found that G9a inhibition of Hepa-1 cells resulted in a 2-fold induction of PTEN mRNA and a marked induction of p21 mRNA, without inducing p53. In contrast, G9a inhibition markedly induced C/EBPβ, a transactivator of p21 and CHOP. BIX-01294 also induced C/EBPβ (8.8 fold), p21 (11 fold), and CHOP (22 fold) in p53-negative Hep3B cells. In HepG2 cells, BIX-01294 also induced p21 mRNA and decreased H3K9me2 of the p21 promoter (ChIP-qPCR analysis). Moreover, exposure of proliferating HepG2, Huh7, and Hep3B cells to BIX-01294 (4 µM) for 72 h resulted in >90% decrease in the numbers of live cells. In contrast, treatment with 8 µM of BIX-01294 for 96 h had no effect on the survival of a differentiated human hepatoma HepaRG cell line. By crossing G9a floxed mice with Alb-cre mice, we have generated mice with adult-hepatocyte-specific knockout of G9a, which appear normal and have normal livers. In conclusion, the present data demonstrate that the G9a specific inhibitor BIX-01294 markedly induces p21 and CHOP in a p53-independent mechanism, probably due to a combined effect of desuppression of C/EBPβ (a transactivator for p21 and CHOP) and/or removal of the suppressive mark H3K9me2 from the p21 promoter. G9a inhibition has potent anticancer effects in both mouse and human hepatoma cells, but has little cytotoxicity in fully differentiated human hepatoma cells, and loss of G9a in mouse liver is well-tolerated under unstressed conditions. Therefore, G9a inhibitors may be a promising new class of epigenetic drugs for the treatment of liver cancer. (Supported by NIH grants RR021940, ES013714, and a KU cancer center grant) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4865.

Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma

RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma

SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma

Cyclin-Dependent Kinase 9 Inhibition As a Potential Treatment for Hepatocellular Carcinoma

[High expression of MYH9 inhibits apoptosis of non-small cell lung cancer cells through activating the AKT/c-Myc pathway]

Comprehensive Profiling of Novel Microrna-9 Targets and a Tumor Suppressor Role of Microrna-9 Via Targeting IGF2BP1 in Hepatocellular Carcinoma

Abstract 4865: Inhibition of histone methyltransferase G9a as a promising new target for the treatment of liver cancer

Sox9 Regulates Self-Renewal and Tumorigenicity by Promoting Symmetrical Cell Division of Cancer Stem Cells in Hepatocellular Carcinoma.

Mir-3682-3p Directly Targets FOXO3 and Stimulates Tumor Stemness in Hepatocellular Carcinoma Via a Positive Feedback Loop Involving FOXO3/PI3K/AKT/c-Myc

Tnfsf9 Exerts an Inhibitory Effect on Hepatocellular Carcinoma

HBV Suppresses ZHX2 Expression to Promote Proliferation of HCC Through Mir-155 Activation

Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway

TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC

ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation

The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma

Sox9/CXCL5 axis facilitates tumour cell growth and invasion in hepatocellular carcinoma

Yin Yang 1‐mediated Epigenetic Silencing of Tumour‐suppressive Micrornas Activates Nuclear Factor‐κb in Hepatocellular Carcinoma

MYH9 Facilitates Cell Invasion and Radioresistance in Head and Neck Cancer via Modulation of Cellular ROS Levels by Activating the MAPK-Nrf2-GCLC Pathway

HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis

A Novel Nine Gene Signature Integrates Stemness Characteristics Associated with Prognosis in Hepatocellular Carcinoma

NAP1L5 Targeting Combined with MYH9 Inhibit HCC Progression Through PI3K/AKT/mTOR Signaling Pathway